Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6809 - 6816 of 12026 results
The HIPAA “Wall of Shame” is Now Easier to Navigate
July 31, 2017| Blog| Viewpoint
Health Care Weekly Preview from ML Strategies – Week of July 31, 2017
July 31, 2017| Blog| Viewpoint
California's Prop 65: More Form Over Substance
July 31, 2017| Blog| Viewpoint
Monkey See… Now, How NOT To Do
July 28, 2017| Blog| Viewpoint
ITC Denies Suspension or Temporary Rescission of Remedial Orders After PTAB Invalidates Patents at Issue
July 28, 2017| Blog| Viewpoint
2017 Nantucket Impact Capitalism Summit Highlights Importance of Impact Investing
July 27, 2017| Blog| Viewpoint
2nd Circ. Offers Insight On 'Class Arbitration' Questions
July 27, 2017| News
Vacation Float: Managing (and Recouping) Unearned Vacation Time
July 26, 2017| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|